Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atrion Co. stock logo
ATRI
Atrion
$414.95
$411.60
$274.98
$613.16
$730.31M0.6218,856 shs36,896 shs
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
$7.49
+4.2%
$6.36
$3.33
$7.50
$1.42B1.321.88 million shs2.28 million shs
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
$0.36
$0.05
$11.78
$5.07M1.2434.54 million shs23.06 million shs
Zogenix, Inc. stock logo
ZGNX
Zogenix
$26.68
$26.52
$11.03
$26.90
$1.50B0.893.76 million shs94 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atrion Co. stock logo
ATRI
Atrion
-2.79%+4.01%+8.89%+22.77%-32.56%
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
+2.71%+4.88%+10.43%+27.89%+83.67%
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
0.00%0.00%0.00%-77.50%-98.92%
Zogenix, Inc. stock logo
ZGNX
Zogenix
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Atrion Co. stock logo
ATRI
Atrion
1.7216 of 5 stars
0.01.02.50.02.63.31.3
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
2.1853 of 5 stars
1.31.00.04.92.51.70.6
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
1.0539 of 5 stars
3.20.00.04.20.00.00.6
Zogenix, Inc. stock logo
ZGNX
Zogenix
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atrion Co. stock logo
ATRI
Atrion
N/AN/AN/AN/A
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
2.50
Moderate Buy$7.500.13% Upside
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
2.33
Hold$7.63∞ Upside
Zogenix, Inc. stock logo
ZGNX
Zogenix
N/AN/AN/AN/A

Current Analyst Ratings

Latest BKD, NSTG, ATRI, and ZGNX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/9/2024
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$9.00
(Data available from 5/3/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atrion Co. stock logo
ATRI
Atrion
$169.33M4.31$19.06 per share21.77$138.02 per share3.01
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
$3.02B0.47$0.91 per share8.21$2.15 per share3.48
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
$127.26M0.00N/AN/A$0.98 per share0.00
Zogenix, Inc. stock logo
ZGNX
Zogenix
$81.69M18.36N/AN/A$6.64 per share4.02

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atrion Co. stock logo
ATRI
Atrion
$19.41M$11.0337.62N/A11.46%8.07%7.37%5/13/2024 (Estimated)
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
-$189.01M-$0.84N/AN/AN/A-6.27%-44.01%-3.75%5/7/2024 (Confirmed)
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
-$159.54M-$3.53N/AN/AN/A-102.44%-548.25%-53.79%N/A
Zogenix, Inc. stock logo
ZGNX
Zogenix
-$209.38M-$4.07N/AN/AN/A-278.38%-91.20%-43.60%N/A

Latest BKD, NSTG, ATRI, and ZGNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
-$0.17N/A+$0.17N/AN/AN/A  
2/29/2024Q4 2023
Atrion Co. stock logo
ATRI
Atrion
N/A$3.65+$3.65$3.65N/A$43.58 million
2/20/2024Q4 2023
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
-$0.19-$0.40-$0.21-$0.40N/A$754.48 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Atrion Co. stock logo
ATRI
Atrion
$8.802.12%+9.65%79.78%21 Years
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
N/AN/AN/AN/AN/A
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
N/AN/AN/AN/AN/A
Zogenix, Inc. stock logo
ZGNX
Zogenix
N/AN/AN/AN/AN/A

Latest BKD, NSTG, ATRI, and ZGNX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/27/2024
Atrion Co. stock logo
ATRI
Atrion
Quarterly$2.202.42%3/14/20243/15/20243/29/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atrion Co. stock logo
ATRI
Atrion
N/A
9.09
2.57
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
9.40
0.80
0.80
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
N/A
2.73
2.02
Zogenix, Inc. stock logo
ZGNX
Zogenix
0.88
3.63
4.74

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Atrion Co. stock logo
ATRI
Atrion
66.19%
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
N/A
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
N/A
Zogenix, Inc. stock logo
ZGNX
Zogenix
N/A

Insider Ownership

CompanyInsider Ownership
Atrion Co. stock logo
ATRI
Atrion
22.82%
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
1.50%
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
3.10%
Zogenix, Inc. stock logo
ZGNX
Zogenix
4.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Atrion Co. stock logo
ATRI
Atrion
7121.76 million1.36 millionNot Optionable
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
25,200189.34 million186.50 millionOptionable
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
55048.12 million46.63 millionOptionable
Zogenix, Inc. stock logo
ZGNX
Zogenix
21856.23 million53.92 millionOptionable

BKD, NSTG, ATRI, and ZGNX Headlines

SourceHeadline
Hwasung Industrial Co Ltd 002460Hwasung Industrial Co Ltd 002460
morningstar.com - March 23 at 1:30 AM
Orally Inhaled DihydroergotamineOrally Inhaled Dihydroergotamine
medscape.com - February 13 at 4:11 PM
MRI in HeadacheMRI in Headache
medscape.com - August 25 at 10:47 PM
Kratom: What We KnowKratom: What We Know
medscape.com - August 13 at 5:03 PM
Alcon (NYSE: ALC)Alcon (NYSE: ALC)
fool.com - July 6 at 8:34 PM
Longeveron Inc Ordinary Shares - Class ALongeveron Inc Ordinary Shares - Class A
morningstar.com - May 21 at 12:24 AM
Dravet Syndrome Market Report 2032: Epidemiology Data, Pipeline ... - Digital JournalDravet Syndrome Market Report 2032: Epidemiology Data, Pipeline ... - Digital Journal
news.google.com - May 10 at 11:58 PM
Global Needle Free Diabetes Management Market Size 2023 ... - The Northwestern ExaminerGlobal Needle Free Diabetes Management Market Size 2023 ... - The Northwestern Examiner
news.google.com - May 8 at 2:44 PM
Global Needle-Free Drug Delivery Systems Market New ... - The Northwestern ExaminerGlobal Needle-Free Drug Delivery Systems Market New ... - The Northwestern Examiner
news.google.com - May 8 at 2:44 PM
Needle Free Injection Systems Market Size Reach Valuation of USD 519.3 Million in 2030 - Emergen Research - openPRNeedle Free Injection Systems Market Size Reach Valuation of USD 519.3 Million in 2030 - Emergen Research - openPR
news.google.com - May 4 at 4:03 PM
Needle Free Diabetes Management Market Forecast 2023 – 2032 ... - Taiwan NewsNeedle Free Diabetes Management Market Forecast 2023 – 2032 ... - Taiwan News
news.google.com - April 28 at 12:42 PM
The Pathophysiological and Pharmacological Basis of Current Drug Treatment of Migraine HeadacheThe Pathophysiological and Pharmacological Basis of Current Drug Treatment of Migraine Headache
medscape.com - April 25 at 2:50 PM
Long-Acting Injectable Antipsychotics Market 2023-2033: Global ... - Taiwan NewsLong-Acting Injectable Antipsychotics Market 2023-2033: Global ... - Taiwan News
news.google.com - April 24 at 9:21 AM
Anti-epileptic Drugs Market Expected to Expand at a Steady 2023 ... - Digital JournalAnti-epileptic Drugs Market Expected to Expand at a Steady 2023 ... - Digital Journal
news.google.com - April 24 at 9:21 AM
Dravet Syndrome Pipeline Assessment (2023 Updates) | In-depth ... - Digital JournalDravet Syndrome Pipeline Assessment (2023 Updates) | In-depth ... - Digital Journal
news.google.com - April 20 at 12:29 AM
Form SC 14D9/A Provention Bio, Inc. Filed by: Provention Bio, Inc. - StreetInsider.comForm SC 14D9/A Provention Bio, Inc. Filed by: Provention Bio, Inc. - StreetInsider.com
news.google.com - April 19 at 7:28 PM
DEA lifts Dravet therapy Finteplas controlled substance status |... - Dravet Syndrome NewsDEA lifts Dravet therapy Fintepla's controlled substance status |... - Dravet Syndrome News
news.google.com - April 18 at 3:52 PM
UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now ... - Longview News-JournalUCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now ... - Longview News-Journal
news.google.com - April 17 at 7:30 PM
Subcutaneous Medicine Delivery Devices Market is poised to grow ... - Digital JournalSubcutaneous Medicine Delivery Devices Market is poised to grow ... - Digital Journal
news.google.com - April 17 at 7:30 PM
Epilepsy Market to Observe Utmost CAGR of 7.78% by 2028, Size ... - Digital JournalEpilepsy Market to Observe Utmost CAGR of 7.78% by 2028, Size ... - Digital Journal
news.google.com - April 17 at 9:27 AM
UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now ... - PR NewswireUCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now ... - PR Newswire
news.google.com - April 17 at 9:27 AM
Lennox Gastaut Syndrome Market to Witness Growth by 2032 | Companies-GlaxoSmithKline, Meda Pharmaceuticals, Ro - openPRLennox Gastaut Syndrome Market to Witness Growth by 2032 | Companies-GlaxoSmithKline, Meda Pharmaceuticals, Ro - openPR
news.google.com - April 14 at 8:40 AM
Needle-Free Injectors Market Robust Expansion is expected to 2030 - Digital JournalNeedle-Free Injectors Market Robust Expansion is expected to 2030 - Digital Journal
news.google.com - April 13 at 5:40 PM
New Trends of Long-acting Injectable Medications Market Demand: Insights and Analysis from Latest Research Rep - openPRNew Trends of Long-acting Injectable Medications Market Demand: Insights and Analysis from Latest Research Rep - openPR
news.google.com - April 12 at 1:29 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Atrion logo

Atrion

NASDAQ:ATRI
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. Its cardiovascular products comprise Myocardial Protection System that delivers fluids and medications, and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. The company's ophthalmic products consist of a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. It manufactures products for safe needle and scalpel blade containment; inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; and one-way and two-way pressure relief valves that protect sensitive electronics and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales force, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.
Brookdale Senior Living logo

Brookdale Senior Living

NYSE:BKD
Brookdale Senior Living Inc. owns, manages, and operates senior living communities in the United States. It operates in three segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRCs). The Independent Living segment owns or leases communities comprising independent and assisted living units in a single community that are primarily designed for middle to upper income seniors. The Assisted Living and Memory Care segment owns or leases communities consisting of freestanding, multi-story communities and freestanding, single-story communities, which offer housing and 24-hour assistance with activities of daily living for the Company's residents. This segment also operates memory care communities for residents with Alzheimer's and other dementias. The CCRCs segment owns or leases communities that provides various living arrangements, such as independent and assisted living, memory care, and skilled nursing; and services to accommodate various levels of physical ability and healthcare needs. It also manages communities on behalf of others. Brookdale Senior Living Inc. was incorporated in 2005 and is headquartered in Brentwood, Tennessee.
NanoString Technologies logo

NanoString Technologies

NASDAQ:NSTG
NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits. The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaboration with Lam Research Corporation for the development of NGS sequencing platform and related assays; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer, as well as collaboration with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington. On February 4, 2024, NanoString Technologies, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Zogenix logo

Zogenix

NASDAQ:ZGNX
Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.